내분비요법이 전립선암의 VEGF발현과 혈관형성에 미치는 영향
Endocrine Therapy Inhibits Expression of Vascular Endothelial Growth Factor and Angiogenesis in Prostate Cancer
문삼영, 김용규,
소속 상세정보
문삼영 ( )
동국대학교
김용규 ( )
중앙대학교 의과대학 비뇨기과학교실
KMID : 0358319990400010029
Abstract
결론
본 연구에서는 21명의 전립선암환자에서 내분비요법의 전과 3개월후에 각각 혈관형성의
정도와 VEGF의 발현을 factor 8 및 VEGF에 대한 면역조직화학염색과 VEGF에 대한
RT-PCR-Southern blot으로 각각 비교분석하였다. 그 결과 1) 전립선암조직에서 양성조직
에 비해 혈관형성이 증가되며, 2) VEGF가 전립선암에서 주된 혈관형성 인자로 작용하고,
3) 전립선암세포의 VEGF발현은 남성호르몬에 의해 유지되며, 4) 전립선암환자에서 내분비
요법은 전립선암의 VEGF발현과 혈관형성을 억제하는 역할을 하며, 이것이 내분비요법의
중요 작용기전중 하나가 되고, 5) 고환절제술과 leuprolein의 전립선암 혈관형성 억제 효과는
동등할 것이라는 결론을 유추할 수 있었다.
Purpose: Angiogenesis is essential for the growth and metastasis of tumors.
Mechanism of angiogenesis of prostate cancer remains to be defined. Vascular
endothelial growth factor(VEGF) is one of the most potent angiogenic factors and we
have previously demonstrated that VEGF was expressed by rat ventral prostate in an
androgen dependent manner. We herein investigated whether VEGF also plays an
important role in tumor angiogenesis of prostate cancer and whether endocrine therapy
inhibits expression of VEGF and angiogenesis in prostate cancer.
Materials and Methods: Frozen tumor tissues were obtained from 21 patients with
prostate cancer before and 3 months after endocrine therapy and angiogenic activity was
analyzed by measuring microvascular density(MVD) using immunohistochemical study
for factor VⅢ and VEGF expression by RT-PCR-Southern blot assay and
immunohistochemical study, respectively.
Results: Prostate cancer showed significantly increased expression of VEGF and MVD
as compared with normal prostatic tissues and benign hyperplastic tissues(p<0.001).
There were significant correlations between VEGF expression and MVD of prostate
cancer tissues. After endocrine therapy, both MVD and VEGF expression in prostate
cancer tissues were significantly decreased as compared with those of before endocrine
therapy(p<0.001). There were no significant differences between bilateral orchiectomy
and leuprolelin therapy in inihibitory effect of VEGF expression and MVD in prostate
cancer tissues.
Conclusions: These results suggest that VEGF may be a major angiogenic factor in
prostate cancer and one of important action mechanisms of endocrine therapy in prostate
cancer may be in its inhibition of VEGF expression and tumor angiogenic activity.
키워드
Prostate cancer; Endocrine therapy; Angiogenesis; VEGF;
원문 및 링크아웃 정보
등재저널 정보